首页> 外文期刊>International Journal of Pharmaceutics >Polymer nanocomposite particles of S-nitrosoglutathione: A suitable formulation for protection and sustained oral delivery
【24h】

Polymer nanocomposite particles of S-nitrosoglutathione: A suitable formulation for protection and sustained oral delivery

机译:S-亚硝基谷胱甘肽的聚合物纳米复合颗粒:一种适合保护和持续口服的制剂

获取原文
获取原文并翻译 | 示例
           

摘要

S-nitrosoglutathione (GSNO) is a nitric oxide (NO) donor with therapeutic potential for cardiovascular disease treatment. Chronic oral treatment with GSNO is limited by high drug sensitivity to the environment and limited oral bioavailability, requiring the development of delivery systems able to sustain NO release. The present work describes new platforms based on polymer nanocomposite particles for the delivery of GSNO. Five types of optimized nanocomposite particles have been developed (three based on chitosan, two based on alginate sodium). Those nanocomposite particles encapsulate GSNO with high efficiency from 64% to 70% and an average size of 13 to 61 mm compatible with oral delivery. Sustained release of GSNO in vitro was achieved. Indeed, chitosan nanocomposites discharged their payload within 24 h; whereas alginate nanocomposites released GSNO more slowly (10% of GSNO was still remaining in the dosage form after 24 h). Their cytocompatibility toward intestinal Caco-2 cells (MTT assay) was acceptable (IC50: 6.07 +/- 0.07-9.46 +/- 0.08 mg/mL), demonstrating their suitability as oral delivery systems for GSNO. These delivery systems presented efficient GSNO loading and sustained release as well as cytocompatibility, showing their promise as a means of improving the oral bioavailability of GSNO and as a potential new treatment. (C) 2015 Elsevier B.V. All rights reserved.
机译:S-亚硝基谷胱甘肽(GSNO)是一氧化氮(NO)供体,具有治疗心血管疾病的潜力。 GSNO的长期口服治疗受到对环境的高度药物敏感性和有限的口服生物利用度的限制,需要开发能够维持NO释放的输送系统。本工作描述了基于聚合物纳米复合颗粒的新平台,用于GSNO的传递。已经开发出五种类型的优化纳米复合颗粒(三种基于壳聚糖,两种基于藻酸钠)。这些纳米复合颗粒以64%至70%的高效率封装了GSNO,平均粒径为13至61 mm,与口服给药相容。 GSNO在体外得以持续释放。的确,壳聚糖纳米复合材料在24小时内释放了有效载荷。而藻酸盐纳米复合材料释放GSNO的速度更慢(剂型24小时后仍残留10%的GSNO)。它们对肠道Caco-2细胞的细胞相容性(MTT分析)是可以接受的(IC50:6.07 +/- 0.07-9.46 +/- 0.08 mg / mL),表明它们适合作为GSNO的口服给药系统。这些递送系统表现出有效的GSNO负载和持续释放以及细胞相容性,显示出它们作为改善GSNO口服生物利用度的手段和潜在的新疗法的希望。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号